31 results about "ALDH2" patented technology

Methods, articles of manufacture and compositions are provided useful for the prevention or amelioration of a symptom of acetaldehyde accumulation or ethanol intolerance in a subject with reduced or absent reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity wherein about 1 mg / kg to about 4 mg / kg 4-methylpyrazole, or an equivalent mass of a 4-MP salt, are to be orally administered to the subject.

The present invention discloses a kit for detecting aldehyde dehydrogenase 2(ALDH2) gene polymorphism by using the single-tube bidirectional allele-specific amplification technology combined with the SNP sensitivity molecular switch technology, and an amplification method and a detection method thereof. The kit genotypes the Glu487Lys(rs671) site on the aldehyde dehydrogenase 2. The kit includes amplification buffer, polymerase, cell lysis buffer and glycerol, and can complete the genotyping for the SNP site in one PCR reaction so as to understand the genotype of the aldehyde dehydrogenase 2 subject and the product activity thereof.

The present invention provides inhibitors of ALDH1A1 activity which have substantially no effect on either ALDH2 or ALDH3A1. Compositions and methods of use, as well as methods to treat cancer using the ALDH1A1 inhibitors, are also provided.

The present invention relates to a method and a set for detecting alcohol metabolizing genes. The present invention provides a method and a reagent for detecting alcohol dehydrogenase (ADH1B) and aldehyde dehydrogenase (ALDH2). The method and the reagent have enough specifity and sensitivity, can save complicated steps for learning the technology, and can save time and manpower. The present invention further provides a method and a set for detecting an individual who has a high cancer risk after consuming alcohol.

Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity.

The invention discloses a kit for screening colorectal cancer hereditary susceptibility genes. The kit comprises colorectal cancer susceptibility gene specificity primers for amplifying a plurality of target regions in a to-be-detected sample, wherein the colorectal cancer susceptibility genes include at least one of rs10795668, MMP2, SMAD7, ADH2, ALDH2, CYP1A2, MMP-1, MTHFR, TP53, VEGF, COX-2, DNMT3B, hMLH1, LOC727677, MMP9, MTRR and TGF-beta 1. The kit can detect a plurality of regions of the colorectal cancer susceptibility genes at the same time, detecting efficiency is improved, detecting cost is reduced, and detecting accuracy and sensitivity are high.

The invention discloses a primer for detecting alcohol metabolizing genes by the aid of pyrosequencing joint sequencing methods, and belongs to the technical field of biological detection. The primer comprises amplification primers shown as SEQ ID NO.1-4 and sequencing primers shown as SEQ ID NO.5-6. Biotin labeling is carried out by 5' ends of the primers shown as SEQ ID NO.1 and SEQ ID NO.3. The invention further discloses application of the primer to simultaneously detecting the polymorphism of SNP (single nucleotide polymorphism) loci rs671 of ALDH2 (acetaldehyde dehydrogenase 2) genes and SNP loci rs1229984 of ADH1B (alcohol dehydrogenase 1B) genes. The primer is high in detection throughput as compared with the traditional ordinary pyrosequencing with only single-SNP polymorphism detection capacity during sequencing reaction in each procedure, the detection time can be effectively shortened, and labor and the cost can be effectively reduced. Besides, the primer and the application have the advantages of accurate detection results, good specificity, high sensitivity, short detection cycle, simplicity in operation and capability of meeting clinical examination requirements.

Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity.

The invention discloses a method for detecting a gene type of a polymorphic site rs671 of a gene ALDH2 (Acetaldehyde Dehydrogenase 2) and a kit. A specific 'inner quality control' mechanism is introduced in a process of detecting the gene type of the polymorphic site rs671 of the gene ALDH2, i.e. an inner contrast cleavage site is introduced into a PCR product; the situation of incomplete cleavage can be identified according to a cleavage atlas; and furthermore, under a condition of the incomplete cleavage and a condition that partial cleavage bands are blurred, the gene type still can be accurately judged, so that the accuracy of a detection result is greatly improved.

The invention discloses an SNP (single nucleotide polymorphism) detection kit for a nitroglycerin drug-sensitive type relevant gene ALDH2 and a use method thereof. The human genome DNA (deoxyribonucleic acid) is used as a template; a corresponding specific primer and a fluorescence probe for detecting the ALDH2*2 type polymorphism are respectively added for forming a real-time fluorescence quantitative PCR (polymerase chain reaction) system; through real time PCR reaction, technicians in the field determine the gene type of the ALDH2 through data collected by a fluorescence quantitative PCR instrument. The SNP detection kit has the advantages of high speed, sensitivity, easy judgment and the like, and is suitable for clinic detection and popularization.

The invention belongs to the technical field of medicinal chemistry, in particular to an amides aldehyde dehydrogenase agonist as well as a synthesis method and application thereof. The amides compound provided by the invention shows the relatively high agonist activity on ALDH2, therefore the compound has the potential for preparing drugs for treating diseases related to ALDH2 activity; (2) the amides compound makes great improvement on the activity and the water solubility compared with a positive control substance, and has the better druggability. In this way, the compound has the good development prospects.

Methods of treating or preventing allergic or pulmonary diseases characterized by endothelial dysfunction with Alda-1 are presented. Treatment of pulmonary endothelial cells subjected to hyperoxia with Alda-1 showed an increase in ALDH2 activity and expression. Treatment with Alda-1 also illustrated a decrease in oxidative stress, a decrease in reactive oxygen species (ROS), a decrease in apoptosis, a decrease in inflammation and an enhancement of mitochondrial membrane potential.

The present invention discloses a reagent kit which detects the genetic susceptibility of the synthetic disease of adult woman. The reagent kit comprises a specific primer pair and a specific fluorescent probe pairs which simultaneously detects the SNP polymorphic genotype on the genes of CYBA, CAT, LPL, LEP, ADIPOQ, SOD3, IL3, NOS3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13, CBS, a routine component which is used for the fluorescent quantitative PCR testing and the like. The reagent kit of the invention evaluates the genetic susceptibility of the synthetic disease of adult woman through simultaneously detecting the mononucleotide polymorphism site genotype which is closely linked to the genetic susceptibility of the synthetic disease of adult woman.

The invention discloses a kit that is used for detecting the genetic predisposition of wine and tobacco damages. The kit comprises particularity primer pairs and particularity fluorescent probe pairs that are used for simultaneously detecting 16 SNP polymorphism genotypes on the genes of ADH2, ALDH2, CYP1A1, CYP2A13, CYP2E1, ENOS, ERCC2, GSTM1, GSTP1, GSTT1, MTHFR, NQO1 and XRCC1 and a routine component that is used for fluorescent quantitative PCR detection, etc. The kit of the invention evaluates the genetic predisposition of wine and tobacco damages by simultaneously detecting the 16 mononucleotide polymorphism locus genotypes that are closely related with the genetic predisposition of wine and tobacco damages.

This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of ALDH2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of ALDH2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat alcoholism and related conditions.

The present invention provides a kit for detecting genetic predisposition of adult male syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 48 SNP polymorphism genotypes on the genes LPL, TNF-alpha, LEP, ADIPOQ, SOD3, IL3, CTLA4, ENOS, ESR2, ERCC1, MTHFR, MS4A2, XRCC1, ALDH2, TNFA, MTR, CCL5, COMT, GSTP1, PPARG, PARP1, OPG, VDR, PON1, ABCA1, MTRR, ERCC2, AT1R, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1, IL6, CYP2A13 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of adult male syndrome by detecting the genotypes of the 48 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of adult male syndrome.

The invention relates to a positive reference taking a GG type of a 1510 site of a human ALDH2*2 gene as a template. The positive reference is characterized in that the positive reference is a reagent mainly comprising a base sequence. The base sequence comprises a human ALDH2*D gene fragment which is as shown in SEQ NO:4, wherein the base site with an underline is the 1510 site of the human ALDH2*D gene, and the 1510 site is used for representing a position wherein the GG type of the human ALDH2*D gene can be mutated to an AA type of the human ALDH2*D gene. The positive reference provided by the invention is used for verifying whether the detection result that a detected sample whether contains the GG type of the 1510 site of the human ALDH2*D gene or not is correct or not, and solves the quality detection problem of the human ALDH2*D gene.

The present invention provides a kit of detecting genetic predisposition of children syndrome. The kit includes specific primer pairs and specific fluorescent probe pairs for detecting 28 SNP polymorphism genotypes on the genes NOS3, CTLA4, ENOS, ERCC1, ERCC2, MTHFR, MTRR, MTR, MS4A2, XRCC1, ALDH2, TNFA, CCL5, PARP1, OPG, VDR, PON1, AGT, CCND1, UCP2, ADH2, ADBR2, APOB, CYP11B2, CYP1A1, CYP2E1, CETP, NQO1 at the same time, and normal components for FQ-PCR detection. The kit of the invention evaluates the genetic predisposition of children syndrome by detecting the genotypes of the 28 SNP polymorphism sites at the same time which is tightly relative to the genetic predisposition of children syndrome.

To specify a molecule associated with the onset of gout so as to provide a method for evaluating a diathesis of uric acid-related diseases and a diathesis of inflammation-related diseases, an evaluation kit for carrying out the method, an inspection object, and a drug, on the basis of the molecule specified above, for contributing to the early treatment and prevention of the uric acid-related diseases and inflammation-related diseases. The molecule includes any one protein and cDNA of CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, MAP3K11, NPT4, ABCG2, HIST1H2BF / HIST1H4E, HIST1H2BE / HIST1H4D and FAM35A, or proteins of combination thereof with GLUT9, NPT1, URAT1, or NXRN2, and is capable of selectively inducing gout. A molecule includes protein and cDNA of an ABCG2 variant and is capable of selectively and ATP-dependently decreasing urate excretion.

Methods of treating or preventing allergic or pulmonary diseases characterized by endothelial dysfunction with Alda-1 are presented. Treatment of pulmonary endothelial cells subjected to hyperoxia with Alda-1 showed an increase in ALDH2 activity and expression. Treatment with Alda-1 also illustrated a decrease in oxidative stress, a decrease in reactive oxygen species (ROS), a decrease in apoptosis, a decrease in inflammation and an enhancement of mitochondrial membrane potential.

The invention discloses a simple and economical one-tube ALDH2 genotyping kit. The kit comprises the following components: a direct-amplification dye method qPCR premixed solution containing three primer groups, a positive plasmid control and a negative control. The kit is characterized in that the three primer groups are as follows: an ALDH2-F upstream primer is shown in SEQ ID NO: 1, an ALDH2-Rdownstream primer is shown in SEQ ID NO: 2, and an ALDH2-MR mutant downstream primer is shown in SEQ ID NO: 3. The kit disclosed by the invention adopts one-tube qPCR reaction, and an extraction stepof a sample is omitted, so that the test cost is greatly saved, and the pollution risk in the extraction process is avoided. The kit is accurate, rapid and low in cost, is particularly suitable for risk analysis of genetic factors such as drinking behavior, alcoholic cirrhosis and liver cancer, and is also a reference method for clinical nitroglycerin guiding medication.

The invention relates to the technical field of medicines, and specially relates to two acetaldehyde dehydrogenase agonists, and a preparation method and application thereof. Specifically, the invention relates compounds shown as a formula I and a formula II, a preparation method of the compounds, and application of the above two compounds and pharmaceutically acceptable inorganic or organic salts to prepare ALDH2 agonists and to prepare medicines for treating alcohol poisoning and to prepare medicines for alleviating alcoholism. The formula I and the formula II are shown in the specification.

The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include temporary ALDH2 deficiency, such as that seen by alcohol poisoning or an ischemic event.

The invention relates to a primer composition for detecting a nitroglycerin drug related gene and a kit. The primer composition comprises a primer group ALDH2 (acetaldehyde dehydrogenase 2). The kit comprises the primer composition. Compared with the prior art, the primer composition and the kit have the advantages that the kit capable of rapidly, sensitively, simply and conveniently detecting gene polymorphism of a nitroglycerin drug treatment effect related gene (ALDH2) is obtained by adopting an ARMS (amplification refractory mutation system) technology and SYBR dye combined method; the kitcomprises a specific ARMS detection primer, an internal control primer and a PCR (polymerase chain reaction) solution, the detecting cost is reduced greatly through designing the ARMS primer and changing an Scorpions probe into an SYBR dye, thus, the kit is more applicable to the detection on polymorphism of the gene ALDH2 of a Chinese patient, has the advantages of high detection speed, high sensitivity, high specificity, simple method and accurate result and is applicable to popularization and application.

The invention relates to the technical field of medicines, and specially relates to two acetaldehyde dehydrogenase agonists, and a preparation method and application thereof. Specifically, the invention relates compounds shown as a formula I and a formula II, a preparation method of the compounds, and application of the above two compounds and pharmaceutically acceptable inorganic or organic salts to prepare ALDH2 agonists and to prepare medicines for treating alcohol poisoning and to prepare medicines for alleviating alcoholism. The formula I and the formula II are shown in the specification.

The invention discloses a nitroglycerin metabolism marker detection kit and a detection method and application thereof. The detection kit is used for detecting the gene polymorphism of a nitroglycerin metabolism marker gene locus ALDH2G1510A, and the kit comprises an ALDH2G1510A amplification primer, an ALDH2G1510A sequencing primer and a positive control. According to the method, ALDH2 (G1510A) is amplified through RPA, a large number of amplification products are rapidly and effectively generated at the constant temperature, single-stranded DNA is specifically captured through an amino-labeled single-stranded DNA analogue directly combined with carboxyl modifier, after washing, a sequencing primer and template DNA are added for annealing, and a sequencing raw material is added for pyrosequencing.

The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include temporary ALDH2 deficiency, such as that seen by alcohol poisoning or an ischemic event.

The invention provides a gene detection reagent kit for evaluating alcohol tolerance. The gene detection reagent kit comprises six amplification primers for three genes including an internal reference gene GAPDH (glyceraldehyde phosphate dehydrogenase), a gene ADH1B (ethanol dehydrogenase 1B) and a gene ALDH2 (acetaldehyde dehydrogenase 2) and five Taq-man probe primers. One of the Taq-man probe primers is positioned at the internal reference gene GAPDH and is used for carrying out FAM fluorescence labeling; two other Taq-man probe primers are SNP (single nucleotide polymorphism) probes positioned at the gene ADH1B and are used for carrying out VIC and ROX (roxithromycin) labeling; the remaining two Taq-man probe primers are SNP probes positioned at the gene ALDH2 and are used for Cy5 and Quasar705 labeling, BHQ is used as a quenching group, and delta ct values can be computed. The gene detection reagent kit has the advantages that the alcohol tolerance of healthy persons can be evaluated by the gene detection reagent kit from the aspect of genes, and accordingly the healthy persons can know the strength and the weakness of alcohol tolerance, can drink alcohol scientifically and can carry on occasion such as party, gathering and banquet related to alcohol culture.

The invention belongs to the technical field of altitude hypoxia tolerance detection and particularly relates to an SNP site associated with altitude hypoxia tolerance adaptability and an applicationthereof. The invention provides an SNP site rs671 of a gene ALDH2 for predicting the altitude hypoxia tolerance adaptability and an application of the SNP site rs671 to preparation of a kit. The SNP site shows, for the first time, that mutation of the site rs671 of the gene ALDH2 causes low activity of the ALDH2, so that aerobic cells, especially myocardial cells cannot be subjected to effective mitophagy like wild-type cells under the stimulation of a hypoxic condition, a large number of functionally impaired mitochondria are accumulated, a transformation process disorder of energy supply metabolism, namely glycolysis metabolism under the hypoxic condition is further generated, abnormal ATP energy supply of the aerobic cells and oxygen consumption surge under the hypoxic condition are caused, cells of a body and even aerobic organs cannot successfully complete a hypoxic adaptation process, and finally the adaptation of the body to an altitude hypoxia environment is hindered.

The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include temporary ALDH2 deficiency, such as that seen by alcohol poisoning or an ischemic event.